TIGIT and neoplasm: The bifunctional adhesin Fap2 has been demonstrated to adhere to cancer cell-specific Gal-GalNAc-moieties while also deactivating tumor-infiltrating lymphocytes (TILs) through the immune cell receptor TIGIT (6, 7).